RTW Investments LP Grows Stake in Arvinas, Inc. (NASDAQ:ARVN)

RTW Investments LP boosted its position in Arvinas, Inc. (NASDAQ:ARVN) by 19.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,334,308 shares of the company’s stock after purchasing an additional 551,979 shares during the period. RTW Investments LP owned about 4.85% of Arvinas worth $63,919,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of ARVN. KBC Group NV increased its stake in Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after purchasing an additional 1,255 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Arvinas in the 4th quarter valued at approximately $171,000. Teacher Retirement System of Texas increased its position in Arvinas by 19.0% during the fourth quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company’s stock worth $274,000 after buying an additional 2,280 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Arvinas by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock worth $279,000 after buying an additional 1,367 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in Arvinas during the fourth quarter worth $332,000. 95.19% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on ARVN shares. Morgan Stanley dropped their price target on Arvinas from $12.00 to $11.00 and set an “equal weight” rating for the company in a research report on Friday, May 9th. Wedbush downgraded Arvinas from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $57.00 to $12.00 in a research report on Wednesday, March 12th. HC Wainwright dropped their price target on Arvinas from $81.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Truist Financial reissued a “hold” rating and set a $11.00 price target (down previously from $21.00) on shares of Arvinas in a research report on Monday, May 5th. Finally, BMO Capital Markets dropped their price target on Arvinas from $20.00 to $10.00 and set an “outperform” rating for the company in a research report on Monday, May 5th. Eight investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, Arvinas presently has a consensus rating of “Moderate Buy” and an average target price of $20.92.

Insider Activity at Arvinas

In other Arvinas news, insider Ian Taylor sold 9,020 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the transaction, the insider now owns 159,121 shares in the company, valued at $2,658,911.91. The trade was a 5.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Noah Berkowitz sold 8,658 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the transaction, the insider now owns 110,023 shares in the company, valued at approximately $945,097.57. This represents a 7.30% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,230 shares of company stock worth $769,402. 4.73% of the stock is owned by insiders.

Arvinas Stock Up 3.1%

Shares of NASDAQ:ARVN opened at $6.26 on Friday. Arvinas, Inc. has a 52 week low of $5.90 and a 52 week high of $37.38. The company has a market cap of $456.92 million, a P/E ratio of -2.26 and a beta of 2.21. The business has a fifty day simple moving average of $7.73 and a 200-day simple moving average of $16.26.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Thursday, May 1st. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the previous year, the company earned ($0.97) EPS. The firm’s revenue was up 646.2% compared to the same quarter last year. Sell-side analysts expect that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.